Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy

Tatsuya Fujino, Yoko Aoyagi, Mariko Takahashi, Ryoko Yada, Naoko Yamamoto, Yuki Ohishi, Akihiko Nishiura, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuzumi, Manabu Nakashima, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta, Munechika Enjoji

Tatsuya Fujino, Laboratory for Clinical Investigation, National Hospital Organization Nagasaki Medical Center, Ohmura, Nagasaki 856-8562, Japan
Yoko Aoyagi, Mariko Takahashi, Ryoko Yada, Naoko Yamamoto, Yuki Ohishi, Akihiko Nishiura, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuzumi, Makoto Nakamuta, Munechika Enjoji, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka 814-0180, Japan
Manabu Nakashima, Munechika Enjoji, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
Masaki Kato, Kazuhiro Kotoh, Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 814-0180, Japan

Author contributions: Fujino T, Nakamuta M and Enjoji M designed the research; Fujino T, Kohjima M, Yoshimoto T, Fukuzumi K, Kato M and Kotoh K performed the research; Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y and Nishiura A analyzed the data; Fujino T and Enjoji M wrote the paper; Nakashima M and Nakamuta M reviewed it.

Supported by The Research Program of Intractable Disease provided by the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-Aid for Clinical Research from the National Hospital Organization of Japan

Correspondence to: Munechika Enjoji, MD, PhD, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. enjoji@adm.fukuoka-u.ac.jp
Telephone: +81-92-8716631 Fax: +81-92-8630389

Accepted: May 18, 2013 Revised: May 16, 2013
Published online: August 6, 2013

Abstract

AIM: To analyzed the association between inosine triphosphatase (ITPA) (rs1127354) genotypes and sustained virological response (SVR) rates in peginterferon (Peg-IFN)α + ribavirin (RBV) treatment.

METHODS: Patients who underwent Peg-IFNα + RBV combination therapy were enrolled (n = 120) and they had no history of other IFN-based treatments. Variation in hemoglobin levels during therapy, cumulative reduction of RBV dose, frequency of treatment withdrawal, and SVR rates were investigated in each ITPA genotype.

RESULTS: In patients with ITPA CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was < 60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. However, SVR rates were equivalent between CC and CA/AA genotypes, and within a subset of patients with Interleukin 28B (IL28B) TT genotype, SVR rates tended to be higher in patients with ITPA CC genotype, although the difference was not significant.

CONCLUSION: ITPA CC genotype was a disadvantageous factor for Peg-IFNα + RBV treatment in relation to completion rates and RBV dose. However, CC genotype was not inferior to CA/AA genotype for SVR rates. When full-length treatment is accomplished, it is plausible that more SVR is achieved in patients with ITPA CC variant, especially in a background of IL28B TT genotype.

© 2013 Baishideng. All rights reserved.

Key words: Chronic hepatitis C; Interleukin 28B; Inosine triphosphatase; Peginterferon; Ribavirin

Core tip: Inosine triphosphatase (ITPA) polymorphism at rs1127354 is significantly associated with hemoglobin decline and reduction of ribavirin (RBV) during peginterferon-α + RBV therapy. However, the effect of the ITPA gene single-nucleotide polymorphism on treatment outcome is still unclear. In this study, ITPA...
INTRODUCTION

Hepatitis C virus (HCV) genotype 1b accounts for around 70% of chronic hepatitis C in Japan.[9-12] A sustained virological response (SVR) in eliminating HCV RNA by peginterferon (Peg-IFN)α + ribavirin (RBV) combination therapy is attained in 40%-50% of individuals with HCV-1b.[6-8] Triple therapy using Peg-IFNα + RBV + telaprevir is anticipated to be effective for SVR in approximately 75% of patients with HCV-1b.[6-8] It is known that polymorphisms located upstream of the Interleukin 28B (IL28B) gene, encoding for the transmembrane receptor, resulting in antiviral activity. STAT (Janus kinase-signal transducer and activator of transcription) pathway through interaction with a cellular receptor, leading to inosine deficiency and protection against RBV-induced ATP depletion.[14-18] Accordingly, the protective genotypes, rs1127354 CA and AA as well as rs7270101 AC and CC, are associated with decreased ITPA activity, which confers protection against RBV-related ATP depletion and hemolytic anemia. The Japanese have the AA genotype exclusively at rs7270101, therefore the CC genotype at rs1127354 is a major predictor of RBV-induced anemia during antiviral combination therapy in Japanese patients infected with HCV-1b.[19,20]

However, it is controversial whether ITPA (rs1127354) CC genotype, which induces heavier hemoglobin decline, affects therapeutic outcomes. From the standpoint of health economics, it is important to examine the significance of factors predicting viral response to antiviral treatments and therapeutic outcomes. In this study, Japanese patients infected with HCV-1b, who had experienced Peg-IFNα + RBV combination therapy, were retrospectively analyzed. Patients were divided into groups according to genotyping of ITPA rs1127354 and IL28B rs8099917. Our primary analysis was focused on the quantitative change from baseline in hemoglobin levels and platelet counts, cumulative reduction of RBV dose, frequency of treatment withdrawal, and estimation of treatment outcome.

MATERIALS AND METHODS

Study patients

This retrospective cohort study was performed in 120 patients with chronic HCV-1b infection who were treated with Peg-IFNα + RBV combination therapy at Kyushu Medical Center Hospital between January 2007 and December 2009. The patients met the following inclusion and exclusion criteria. Inclusion criteria were: (1) baseline serum HCV RNA levels > 5.0 log IU/mL; and (2) Japanese patients aged 20-65 years at study entry. Exclusion criteria were: (1) decompensated liver cirrhosis; (2) serum hepatitis B surface antigen; (3) hepatocellular carcinoma or its history; (4) autoimmune hepatitis, alcoholic liver disease, hemochromatosis, or chronic liver disease other than chronic hepatitis C; (5) chronic renal disease or creatinine clearance < 50 mL/min at baseline; (6) hemoglobin < 12 g/dL, neutrophil < 1500/µL or platelets < 100000/µL at baseline; and (7) history of receiving IFN-based treatment. All patients gave consent for analysis of SNPs in ITPA and IL28B genes. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kyushu Medical Center. Written informed consent was obtained from each patient.

Antiviral treatment

Peg-IFNα2b (1.5 µg/kg) or Peg-IFNα2a (180 µg) was injected subcutaneously once weekly. RBV (600-1000 mg/d) was administered after breakfast and dinner. The RBV dose was adjusted by body weight: 600 mg for < 60 kg; 800 mg for 60-80 kg; and 1000 mg for > 80 kg. As a standard combination therapy, Peg-IFNα and RBV were continued for 48 wk. Treatment duration was extended up to...
Table 1 Baseline characteristics of patients

| Baseline characteristics | ITPA polymorphism (rs1127354) | *P* value |
|--------------------------|---------------------------------|----------|
|                          | CA/AA (n = 37)                  | CC (n = 83) |
| Age (yr)                 | 61 ± 8                          | 59 ± 11  | NS      |
| Gender: male/female      | 18/19                           | 37/46    | NS      |
| HCV RNA (log IU/mL)      | 6.2 ± 0.6                       | 5.9 ± 0.5 | NS      |
| Hemoglobin (g/dL)        | 13.4 ± 1.5                      | 13.8 ± 1.7 | NS    |
| WBC (×10^3/μL)           | 4.7 ± 1.2                       | 5.0 ± 1.5 | NS      |
| Platelet (×10^9/μL)      | 18.0 ± 6.0                      | 18.0 ± 7.0 | NS     |
| AST (IU/L)               | 56.8 ± 34.9                     | 58.2 ± 42.3 | NS    |
| ALT (IU/L)               | 65.5 ± 40.0                     | 68.4 ± 56.8 | NS    |
| GGT (IU/L)               | 56.1 ± 52.3                     | 55.3 ± 49.4 | NS     |
| AFP (ng/mL)              | 5.3 ± 4.0                       | 24.2 ± 61.8 | NS      |
| Staging: F1/F2/F3        | 19/16                           | 49/27    | NS      |
| IL28B: TT/TG + GG        | 29/8                            | 53/30    | NS      |

ITPA: Inosine triphosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein; NS: Not significant; HCV: Hepatitis C virus; IL28B: Interleukin 28B.

72 wk in some patients in whom HCV RNA first became undetectable after week 12 but before week 48, SVR was defined as undetectable serum HCV RNA for 24 wk after treatment completion. Rapid virological response (RVR) and early virological response (EVR) were defined as undetectable serum HCV RNA at 4 wk and 12 wk of Peg-IFNα + RBV treatment, respectively. The RBV dose was reduced by 200 mg in patients receiving 600 or 800 mg (by 400 mg in those receiving 1000 mg) when hemoglobin decreased to < 12 g/dL, and by another 200 mg when it was < 10 g/dL. RBV was withdrawn or stopped temporarily when hemoglobin levels decreased to < 8.5 g/dL. Dose of Peg-IFNα2b (or Peg-IFNα2a) was reduced by 50% when the leukocyte count decreased to < 1500/μL, neutrophil count to < 750/μL, or platelet count to < 800000/μL; Peg-IFNα2b or Peg-IFNα2a was withdrawn when the above measures were decreased to < 1000/μL, < 500/μL or < 50000/μL, respectively.

**Laboratory data**

Hematological, biochemical, and virological parameters were determined by the clinical laboratory at Kyushu Medical Center. Serum HCV RNA concentrations were determined by the COBAS TaqMan polymerase chain reaction (PCR) HCV test (Roche Diagnostics, Tokyo, Japan). Genotyping for the IL28B (rs8099917) and ITPA (rs1127354) polymorphisms was performed by TaqMan SNP Genotyping Assays (Applied Biosystems, Branchburg, NJ, United States) that apply a PCR-based restriction fragment length polymorphism assay.

**Statistical analysis**

Statistical analysis was performed using JMP software (SAS Institute Inc., Cary, NC, United States). Differences between categorical variables were analyzed using Fisher’s exact test or *χ*² test. Mann-Whitney *U* test was used for continuous variables. Multivariate analysis was used to identify factors independently associated with the achievement of SVR.

**RESULTS**

**Association between ITPA deficiency and hemoglobin decline**

Baseline characteristics of 120 enrolled patients are shown in Table 1. The study population included 83 patients with major (CC) genotype and 37 patients with minor (CA/AA) genotype of ITPA at rs1127354. Within listed items, no significant difference was seen between ITPA CC and CA/AA groups. Chronological variation of hemoglobin levels and platelet count during Peg-IFNα + RBV therapy is shown in Figure 1. As reported previously, hemoglobin decline was obvious in patients with ITPA CC genotype (rs1127354) and a significant difference was seen at week 1, 2, 4, 12 and 24 (Figure 1A), meaning that ITPA 4 deficiency due to CA/CC genotype was associated with slower hemoglobin decline early in treatment. The greatest difference in mean hemoglobin reduction was found at week 4, while platelet reduction was temporarily heavier in patients with ITPA CA/AA genotype at week 2 and 4 (Figure 1B). Leukocyte and neutrophil counts were equivalent between ITPA genotype CC and CA/AA...
groups during treatment (data not shown).

Treatment outcome in each genotype of ITPA
As a result of hepatocellular carcinoma, therapeutic inefficiency, or adverse events, such as depression, appetite loss, easy fatigability, retinal hemorrhage, and hemolytic anemia, Peg-IFNα + RBV therapy was discontinued in 18 patients with ITPA CC genotype (21.7%) and 6 patients with CA/AA genotype (16.2%). Moreover, serious reduction of RBV administration (< 60% of scheduled total dose) was compelled in significantly more patients with CC genotype compared with the CA/AA genotype. The percentage of patients receiving < 60% total RBV dose, including patients with treatment interruption/withdrawal, was significantly higher for the CC genotype (37.3% vs 21.6%, P < 0.05). To investigate the influence of dose reduction of Peg-IFN on treatment outcome, we also analyzed the dose of Peg-IFN administered for each rs1127354 genotype, and > 70% of the expected total dose was administered to all patients with treatment completion (data not shown). SVR rates were analyzed according to the total RBV dose and ITPA genotype (Table 2). In the whole population, SVR rates were higher in ITPA genotype CC than CA/AA genotype (44.6% vs 40.5%), although the difference was not significant. SVR rates tended to be higher for the CC genotype than the CA/AA genotype in patients with > 60% total RBV dose (58.5% vs 48.3%) or < 60% total RBV dose (20.0% vs 12.5%), but there were no significant differences between the ITPA genotypes.

SVR, RVR and EVR rates were determined for IL28B (rs8099917) and ITPA (rs1127354) genotypes (Table 3). In a subset of patients with IL28B TT genotype, RVR, RVR + EVR and SVR showed higher rates in patients

| Table 2 | Sustained virological response rates according to total ribavirin dose in each inosine triphosphatase genotype |
|---------|----------------------------------------------------------------------------------------------------------|
| ITPA genotype (rs1127354) | Patients with > 60% total RBV dose | Patients with < 60% total RBV dose | Total |
| CA + AA | 48.5% (14/29) | 12.5% (1/9) | 40.5% (15/37) |
| CC | 58.5% (31/53) | 20.0% (6/30) | 44.6% (37/83) |

Each group includes patients in whom treatment was withdrawn. RBV: Ribavirin; ITPA: Inosine triphosphatase.

| Table 3 | Virological response according to classification by inosine triphosphatase and interleukin 28B single-nucleotide polymorphisms n (%) |
|---------|--------------------------------------------------------------------------------|
| Virological response | IL28B: TT | IL28B: TG + GG |
| CA + AA (n = 29) | CA + AA (n = 8) | CC (n = 53) | CA + AA (n = 8) | CC (n = 53) |
| RVR | 10 (10) | 18 (62) | 23 (44) | 10 (10) | 18 (62) |
| RVR + EVR | 18 (62) | 35 (66) | 53 (48) | 1 (12.5) | 8 (26.6) |
| SVR | 13 (44) | 29 (54) | 42 (79) | 2 (25.0) | 8 (26.6) |

1 Inosine triphosphatase (ITPA). SVR: Sustained virological response; RVR: Rapid virological response; EVR: Early virological response; IL28B: Interleukin 28B.

with ITPA CC genotype compared with CA/AA genotype, although the difference was not significant. In a subset of patients with IL28B TG/GG genotype, SVR rates were equivalent between CC and CA/AA genotypes.

When background of SVR and non-SVR patients was compared, there was a significant difference in age, HCV RNA concentrations, platelet counts, staging, and IL28B SNPs, but not in ITPA SNPs (Table 4). Table 5 shows the result of multivariate analysis for predictive factors associated with SVR. The multivariate analysis proved that viral load (HCV RNA < 6.0 log IU/mL) and IL28B TT (rs8099917) were independent factors for SVR.

DISCUSSION
It has been shown that the SNP (rs8099917) in the IL28B gene is strongly associated with response to IFN-based therapy for chronic HCV-1b infection, and the SNP (rs1127354) in the ITPA gene predicts RBV-induced anemia in the Japanese population. In this study, patients with ITPA (rs1127354) genotype CC showed a higher degree of hemoglobin reduction in response to Peg-IFNα + RBV treatment at week 1, 2, 4, 12 and 24 compared with patients in the CA/AA genotype.
with those with the CA/AA genotype (Figure 1A). The greatest difference in mean hemoglobin reduction was found at week 4. These findings confirmed the reported evidence that ITPA deficiency (rs1127354 CA/AA variants) renders protection against the development of RBV-induced hemoglobin decline in Japanese patients infected with HCV-1b. The exact mechanism by which ITPA deficiency protects against RBV-induced hemolysis has yet to be resolved. One postulated mechanism for the development of anemia is the accumulation of triphosphorylated RBV in erythrocytes, causing eventual oxidative damage to erythrocyte membranes, and ITPA deficiency may confer protection against RBV-induced ATP reduction by substituting for erythrocyte GTP, which is depleted by RBV in the biosynthesis of ATP.

Thrombocytopenia, which leads to poor treatment efficacy because of the initial or early dose reduction of Peg-IFNα, is one of the critical adverse events caused by IFN-based antiviral therapy. A previous study has reported that the ITPA (rs1127354) CA/AA genotype is independently associated with a greater reduction in platelet count as well as protection against the reduction in hemoglobin, whereas patients with the CC genotype have significantly less reduction in mean platelet count. We also evaluated whether genetic variants in the ITPA gene were associated with IFN-induced thrombocytopenia. In this study, CC genotype showed lesser trend of reduction at week 2 and 4 compared with CA/AA genotype (Figure 1B). The result may support the association of ITPA gene SNP (rs1127354) with platelet decline in response to Peg-IFNα + RBV treatment.

Hemoglobin reduction often necessitates dose reduction of RBV and premature withdrawal from therapy, therefore the ITPA (rs1127354) genotype CC may be considered as a disadvantageous factor for Peg-IFNα + RBV treatment. However, although ITPA polymorphisms are significantly associated with RBV-induced anemia, their effect on therapeutic outcome is unclear. Some studies have shown no association, and others have reported a possible association with treatment outcomes in chronic hepatitis C patients. In the present study, although there was no significant association between ITPA polymorphisms and treatment outcome, there was a trend towards higher SVR rates in patients with ITPA CC genotype, which seemed to contradict previous studies. The different outcome among the institutes may be due to the difference of inclusion and/or exclusion criteria. In this study, the relationship between IL28B and ITPA variants were additionally analyzed on treatment outcome. When analyzed in the patients available for treatment outcome, all patients were administered ≥70% of the scheduled total Peg-IFNα dose, but the incidence of RBV dose reduction (<60% of the scheduled dose) and withdrawal was significantly higher in patients with the rs1127354 genotype CC. However, the rate of SVR tended to be higher in patients with the CC genotype, especially in a subset of patients with the favorable TT genotype at rs8099917 of IL28B, although the difference was not significant between the CC and CA/AA genotypes (Tables 2 and 3). Independent favorable predictors for SVR identified in multivariate analysis were low viral load (HCV RNA < 6.0 log IU/mL) and TT genotype at rs8099917 of IL28B, but not CC genotype at rs1127354 of ITPA (Table 5).

There were several limitations to this study. (1) Because of the small sample size which may have contributed to the loss of significance observed or some statistical errors, this study may be ranked at preliminary status; (2) Because of the retrospective nature of the study, enrolled patients may not represent the standard Japanese population infected with HCV; (3) Several other significant SNPs, which have been detected in ITPA as well as IL28B, may have influenced and distorted the results; and (4) Mutations in other genes and non-genetic factors that may affect response to antiviral therapy against chronic hepatitis C were not determined.

In conclusion, the SVR rates tended to be higher in patients with the CC genotype than the CA/AA genotype, especially in a subset of patients with IL28B (rs8099917) TT genotype, despite a higher rate of RBV dose reduction and treatment withdrawal. Multivariate analysis identified IL28B SNP (rs8099917) and HCV RNA as independent predictors of SVR. It is plausible that, in a background of IL28B (rs8099917) TT genotype, more SVR is achieved in patients with ITPA CC variant when full-length (duration of 48 or 72 wk) treatment is accomplished. These findings indicate that ITPA (rs1127354) CC genotype is by no means inferior to the CA/AA genotype for viral response to Peg-IFN + RBV combination therapy.

**COMMENTS**

**Background**

A single-nucleotide polymorphism (SNP) at rs1127354 of the inosine triphosphatase (ITPA) gene is associated with hemoglobin decline during peginterferon (Peg-IFN) + ribavirin (RBV) combination therapy in patients with hepatitis C virus infection. However, the effect of the ITPA gene SNP on treatment outcome has not been fully elucidated. Authors analyzed the association between ITPA (rs1127354) genotypes and sustained virological response (SVR) rates in Peg-IFNα + RBV treatment.

**Research frontiers**

ITPA CC genotype was a disadvantageous factor for Peg-IFNα + RBV treatment in relation to completion rates and RBV dose. However, CC genotype was not inferior to CA/AA genotype for SVR rates. When full-length treatment is accomplished, it is plausible that more SVR is achieved in patients with ITPA CC variant, especially in a background of interleukin 28B (IL28B) TT genotype.

**Innovations and breakthroughs**

In patients with ITPA CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was < 60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. However, SVR rates were equivalent between CC and CA/AA genotypes, and within a subset of patients with IL28B (rs8099917) TT genotype, SVR rates tended to be higher in patients with ITPA CC genotype, although the difference was not significant.

**Peer review**

The topic is interesting and relevant. The manuscript is well written and concise.

**REFERENCES**

1. Enomoto N, Takada A, Nakao T, Date T. There are two ma-
or types of hepatitis C virus in Japan. Biochem Biophys Res Commun 1990; 170: 1021-1025 [PMID: 2117923 DOI: 10.1016/0006-291X(90)90494-5].

2 Hayashi K, Fukuda Y, Nakano J, Katanou Y, Toyoda Y, Yokozaki S, Hayakawa T, Morita K, Nishimura D, Kato K, Urano F, Takamatsu J. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res 2003; 25: 409-414 [PMID: 12699851 DOI: 10.1016/S1386-6346(03)00164-0].

3 Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçalves FL, Häussinger D, Diago M, Carosi G, Dhumaleau D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12342553 DOI: 10.1056/NEJMoa020047].

4 Hadziyannis SJ, Sethe H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrell AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676 DOI: 10.1056/NEJMoa031489-10-20040320-00101].

5 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff- man M, Reindollar R, Goodman ZD, Kouri K, Ling M, Albrecht J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06125-2].

6 Hézode C, Forestier N, Dushelko G, Ferenci P, Pol S, Goesser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, Gjervik K, Lin A, Ackrell AM. Telaprevir with peginterferon and ribavirin for chronic hepatitis C genotype 1 infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650].

7 McHutchison JG, Elsner GT, Gordon SC, Jacobson IM, Sulkowski M, Kauflman R, McNaughton E, Lin A, J. Telaprevir with peginterferon and ribavirin for chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676 DOI: 10.1056/NEJMoa031489-10-20040320-00101].

8 Akuta N, Suzuki F, Seko Y, Kawa- muraya Y, Sazaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase S, Ikeda K, Kumada H. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previously non-responders infected with HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI: 10.1056/NEJMoa0806104].

9 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Goldstein DB. ITPA gene variants protect against anemia induced by ribavirin therapy in patients coinfected with HIV and hepatitis C virus. J Mol Biol 2009; 392: 602-613 [PMID: 19631656 DOI: 10.1016/j.jmb.2009.07.051].

10 Suzuki F, Suzuki Y, Akuta N, Sekazi H, Hinakawa M, Kawa- muraya Y, Hosaka T, Kobayashi M, Saitoh S, Arase S, Ikeda K, Kobayashi M, Chayama K, Kanatani N, Nakamura Y, Miyakawa Y, Kumada H. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-421 [PMID: 21246582 DOI: 10.1002/hep.24058].

11 Fujino T, Takahashi M, Watanabe M, ITPA gene variant protects against anemia induced by ribavirin therapy and effect of peg-interferon alfa-2a and ribavirin for chronic hepatitis C. J.Gastroenterol 2010; 45: 1063-1071 [PMID: 20977565 DOI: 10.1111/j.1872-034X.2010.00741.x].

12 Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy—a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology 2010; 139: 1190-1197 [PMID: 20637204 DOI: 10.1053/j.gastro.2010.06.071].

13 Azakami T, Hayes CN, Sazaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Akuta N, Saitoh S, Arase S, Ikeda K, Chayama K. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peginterferon plus ribavirin therapy. J Mol Biol 2011; 413: 1048-1057 [PMID: 21803919 DOI: 10.1002/jm.22069].

14 Osinusi A, Naggie S, Poonsawat P, Trippler M, Yu Z, Funk E, Schlach J, Fishbein D, Masur H, Polis M, Kottilt S. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Mol Biol 2012; 418: 1063-1114 [PMID: 22585729 DOI: 10.1002/jm.23302].

15 De Franceschi L, Favotto G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanizal AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients
with chronic hepatitis C virus infection: role of membrane oxidative damage. *Hepatology* 2000; 31: 997-1004 [PMID: 10733558 DOI: 10.1053/he.2000.5789]

25 **Russmann S**, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. *Curr Med Chem* 2006; 13: 3351-3357 [PMID: 17168855 DOI: 10.2174/0929296706778773059]

26 **Hitomi Y**, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. *Gastroenterology* 2011; 140: 1314-1321 [PMID: 2199653 DOI: 10.1053/j.gastro.2010.12.038]

27 **Tanaka Y**, Kurosaiki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsushashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hisa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Toku-naga K, Mizokami M. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. *Hum Mol Genet* 2011; 20: 3507-3516 [PMID: 21659334 DOI: 10.1093/hmg/ddr249]

28 **Thompson AJ**, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. *Gastroenterology* 2010; 139: 1181-1189 [PMID: 20547162 DOI: 10.1053/j.gastro.2010.06.016]

29 **Thompson AJ**, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV/3 but do not decrease dose reductions of RBV or increase SVR. *Hepatology* 2011; 53: 389-395 [PMID: 21274861 DOI: 10.1002/hep.24068]

30 **Eskesen AN**, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. *Eur J Gastroenterol Hepatol* 2012; 24: 890-896 [PMID: 22584257 DOI: 10.1097/MEG.0b013e3283546efd]

31 **Doyle JS**, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. *Best Pract Res Clin Gastroenterol* 2012; 26: 413-427 [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004]

P- Reviewers Chamulitrat W, Muller T, Swierczynski JT
S- Editor Wen LL  L- Editor A  E- Editor Ma S
